Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNTech SE - ADR (BNTX) vs Coinbase Global, Inc. (COIN) Price & Performance

BioNTech SE - ADRTrade
Coinbase Global, Inc.Trade

Price performance (Past 24H)

Key statistics

BioNTech SE - ADR vs Coinbase Global, Inc. — how do they compare? BioNTech SE - ADR trades at $92.94 (market cap $23.31B), while Coinbase Global, Inc. trades at $149.16 (market cap $39.20B). The key difference: Coinbase Global, Inc. is the larger of the two by market cap, and BioNTech SE - ADR is trading nearer its 52-week high, Coinbase Global, Inc. nearer its low. Which is the better fit depends on your goals.

BNTXCOIN
Market Cap
$23.31B$39.20B
Sector
HealthTechnology
52-Week High
$119.34$387.27
52-Week Low
$83.89$141.09
Enterprise Value
$6.60B$36.85B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNTech SE - ADR

BioNTech (BNTX) trades at $92.72, down 0.09% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of €106 million, missing expectations due to weak COVID-19 vaccine demand, and lowered its 2026 sales outlook. Despite negative profitability metrics (net income margin -63.64%, ROE -9.3%), the balance sheet remains strong with $16.78 billion in cash. Analyst consensus is strongly bullish with 87.5% buy ratings and a $121 price target.

The outlook for BNTX hinges on its oncology pipeline development amid declining COVID revenue. Investment opportunity exists in the discounted valuation relative to cash reserves and potential pipeline catalysts. Key risks include execution on pipeline transitions, competitive pressure, and ongoing vaccine demand volatility. The stock trades near cash value, implying the market assigns minimal value to its advanced clinical programs.

Coinbase Global, Inc.

COIN trades at $150.35, up 1.12% with bearish technical signals but strong analyst support (55% buy ratings). The company reported mixed Q2 2026 results with revenue and EPS misses, though it achieved a record 10.3% global trading volume share. Fundamentals show revenue growth from $3.1B in 2023 to $7.2B in 2025, but profitability remains volatile with recent quarterly losses.

The stock faces near-term pressure from earnings misses and crypto market volatility, but long-term potential exists through business diversification beyond retail trading. Key risks include competitive threats and regulatory uncertainty, while the $207.20 consensus price target suggests 38% upside if execution improves.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

Read more on BNTX

About Coinbase Global, Inc.

Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.

Read more on COIN